Balanced news tone
News Sentiment
NVAX sentiment intelligence
Novavax Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-4.2% over one week, +5.1% over four weeks, trend active, and near fair-value range.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Market source
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Market source
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Market source
Novavax Inc stock (US6707721049): Analyst consensus points to hold as NVAX trades near 11 USD
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 01 Jun 2026 07:00
- Source
- Ad Hoc News
Novavax Inc stock (US6707721049): shares trade around USD 10 after recent volatility and licensing f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Ad Hoc News
Novavax Inc stock (US66987V1098): NVAX trades at $11.09 on Nasdaq
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Ad Hoc News
Why Novavax (NVAX) Stock Is Trading Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Market source
Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 May 2026 07:00
- Source
- Ad Hoc News
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Novavax stock (US66987V1098): Latest developments and business update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Ad Hoc News
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Novavax (NASDAQ:NVAX) Surprises With Strong Q1 CY2026, Stock Soars
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Market source
Is It Time To Reconsider Novavax (NVAX) After A 95% Five Year Share Price Fall
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- simplywall.st
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Apr 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Apr 2026 07:00
- Source
- Market source
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- StockStory
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jan 2026 08:00
- Source
- Market source
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Jan 2026 08:00
- Source
- simplywall.st
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jan 2026 08:00
- Source
- simplywall.st
Novavax Stock Suffers Sharpest Drop In Months After $225M Debt Deal; Retail Still Leans Bullish
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 21 Aug 2025 07:00
- Source
- Stocktwits
Novavax, Inc.'s (NASDAQ:NVAX) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 03 Aug 2025 07:00
- Source
- simplywall.st
Novavax sinks on concerns about COVID vaccine maker's prospects
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Mar 2023 08:00
- Source
- Reuters
Novavax confident Covid vaccine will receive FDA authorization in June after delays
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2022 07:00
- Source
- CNBC
COVID-19 vaccinemaker Novavax faces manufacturing setback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Aug 2021 07:00
- Source
- Science | AAAS
Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 11 Jan 2021 08:00
- Source
- Reuters